Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of VitamIN K2 supplementaTion on PET/MRI in Carotid Artery Disease (INTRICATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04010578
Recruitment Status : Not yet recruiting
First Posted : July 8, 2019
Last Update Posted : July 8, 2019
Sponsor:
Collaborator:
Horizon 2020 - European Commission
Information provided by (Responsible Party):
Felix Mottaghy, Academisch Ziekenhuis Maastricht

Brief Summary:

Atherosclerosis is a disease of the arteries and is the result of various factors such as high blood cholesterol or diabetes, which lead to accumulations of fats, cells, and calcium deposits (i.e. plaques). It has been shown that people with a rapid increase in the amount of calcium deposits have a higher risk for stroke and heart attack than people with a decreased amount.

Previous scientific research has shown that a protein called Matrix Gla Protein plays an important role in the prevention of calcification. This protein works well only if there is enough Vitamin K in the blood vessels. In a large human studies, it has been shown that especially Menaquinone-7 (a form of Vitamin K2) is best absorbed by blood vessels.

Over the last years, fluorine-18 sodium fluoride (18F-NaF) positron emission tomography (PET) emerged as a reliable clinical imaging tool able to detect micro-calcification in the blood vessels. Therefore, the present study will use 18F-NaF PET in combination with magnetic resonance imaging (MRI) to assess the influence of vitamin K supplementation in the development of arterial micro-calcification in the context of atherosclerosis.

The present study would like to confirm that vitamin K2 supplementation induces a significant reduction in the degree of micro-calcification from carotid artery disease patients, when comparing to a placebo, after 3 months.

This will be a prospective double blind randomised controlled feasibility study, in which one group will receive a vitamin K2 supplementation compared to a control group receiving a placebo.


Condition or disease Intervention/treatment Phase
Coronary Artery Disease Carotid Artery Disease Dietary Supplement: Menaquinone-7 Other: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: One group will receive a vitamin K2 supplementation and the control group will receive a placebo.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Vitamin K2 Supplementation on 18F-NaF PET/MRI in Patients With Carotid and Coronary Artery Disease
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : October 1, 2021
Estimated Study Completion Date : February 1, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Menadione

Arm Intervention/treatment
Experimental: Vitamin K2 supplementation
Patients will receive a daily vitamin K2 supplementation for 3 months.
Dietary Supplement: Menaquinone-7
Patients will receive 360 micro-grams of Menaquinone-7 per day.

Placebo Comparator: Placebo
Patients will receive a daily placebo for 3 months.
Other: Placebo
Patients will receive a placebo each day.




Primary Outcome Measures :
  1. The change in time of vascular micro-calcification via (18)F-NaF PET/MRI [ Time Frame: 3 months follow-up ]
    The primary outcome of this study is the mean rate of the change in time of vascular micro-calcification in the carotid arteries, measured as a difference between the intervention group and placebo group in (18)F-NaF uptake via hybrid PET/MRI after the 3 months of treatment.


Secondary Outcome Measures :
  1. The change in time of vascular calcification via coronary artery calcification score [ Time Frame: 3 months follow-up ]

    Investigating whether vitamin K2 supplementation can diminish, halt or even reverse the development of arterial micro-calcification in the coronary arteries, measured as a difference between the intervention group and placebo group in coronary artery calcification score after the 3 months.

    The Agatston coronary artery calcification score isis a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an non-contrast low-dose CT scan. The score ranges from 0 arbitrary units to > 400. The higher the value of the score, the higher the degree of calcification is in the coronary arteries; hence, lower values usually represent a better outcome.


  2. The correlation between (18)F-NaF PET/MRI and coronary artery calcification score [ Time Frame: 3 months follow-up ]

    The correlation between the uptake of (18)F-NaF at 3 months and the coronary artery calcification score.

    The Agatston coronary artery calcification score isis a semi-automated tool to calculate a score based on the extent of coronary artery calcification detected by an non-contrast low-dose CT scan. The score ranges from 0 arbitrary units to > 400. The higher the value of the score, the higher the degree of calcification is in the coronary arteries; hence, lower values usually represent a better outcome.


  3. The influence of vitamin K2 supplementation on MRI parameters [ Time Frame: baseline vs 3 months follow-up ]
    Investigating whether vitamin K2 supplementation can influence the fibrous cap status on the MRI.


Other Outcome Measures:
  1. The influence of vitamin K2 supplementation on carotid intima-media thickness [ Time Frame: baseline vs 3 months follow-up ]
    Investigating whether vitamin K2 supplementation can influence the carotid intima-media thickness



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Asymptomatic carotid artery disease on at least one side with a degree of stenosis > 25% (according to on the ECST criteria). If the patient has a symptomatic carotid artery disease on the contra-lateral side, he/she will still be included in the study, if intensified medical treatment for this symptomatic stenosis (e.g. statins, antiplatelet medication) was started ≥ 6 month before inclusion of the patient. This protocol was chosen in order to widely assure a stable situation on the plaque(s), which avoids an overspill from this medication on the assumed effects of the vitamin K supplementation.
  • Age older than 18 years
  • Signed informed consent provided

Exclusion Criteria:

  • Antiplatelet or cholesterol lowering medication started within the past 6 months
  • Chronic or paroxysmal atrial fibrillation
  • Presence or scheduled coronary or carotid revascularisation procedure (e.g. stent implantation, coronary artery bypass graft, balloon-dilatation, endarterectomy, angioplasty)
  • History of myocardial infarction or stroke
  • Malignant disease (except for treated basal-cell or squamous cell carcinoma)
  • Use of vitamin K antagonists or any other anticoagulation treatment
  • A life-expectancy < 1 year
  • Claustrophobia
  • Presence of a pacemaker, intra-cardiac defibrillator, or metallic implant (e.g. vascular clip, neuro-stimulator, cochlear implant)
  • Body weight > 130kg or body habitus that does not fit into the gantry
  • Pregnancy or wish to become pregnant in the near future
  • Breast feeding
  • (History of) metabolic or gastrointestinal disease
  • Use of vitamin K-containing supplements or vitamin K-rich foods (i.e. soya)
  • Chronic inflammatory disease
  • Systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
  • Corticoid treatment
  • Participation in a clinical study more recently than one month before the current study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04010578


Contacts
Layout table for location contacts
Contact: Felix M Mottaghy, MD, PhD +31 43 3874746 felix.mottaghy@mumc.nl
Contact: Alexandru Florea, MD +49 241 80 89584 aflorea@ukaachen.de

Sponsors and Collaborators
Academisch Ziekenhuis Maastricht
Horizon 2020 - European Commission
Investigators
Layout table for investigator information
Principal Investigator: Felix M Mottaghy, MD, PhD Maastricht University Medical Center

Layout table for additonal information
Responsible Party: Felix Mottaghy, Univ.-Prof. Dr. med., Academisch Ziekenhuis Maastricht
ClinicalTrials.gov Identifier: NCT04010578     History of Changes
Other Study ID Numbers: NL69450.068.19
First Posted: July 8, 2019    Key Record Dates
Last Update Posted: July 8, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All IPD that underlie results in a publication will be shared.
Supporting Materials: Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: IPD will be shared stating with 6 months after publication.
Access Criteria: Access criteria will be discussed with all the study members, then it will be published.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Felix Mottaghy, Academisch Ziekenhuis Maastricht:
Vitamin K2
18F-NaF
hybrid PET/MRI
Coronary artery calcification score
Menaquinone-7
Carotid Artery Disease
Coronary Artery Disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Carotid Artery Diseases
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vitamins
Vitamin K
Vitamin K 2
Vitamin MK 7
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants